Stefan Dirnhofer,Yoshito Nishimura,Angela Dispenzieri
Stefan Dirnhofer
Castleman disease is a term that represents a spectrum of diseases whose driving factors are poorly understood. Increased interest prompted by the Castleman's Disease Collaborative Network has led to a better understanding of classification...
Multiple Myeloma Unpacked [0.03%]
解读多发性骨髓瘤
Francesca Gay,Edoardo Marchetti,Giuseppe Bertuglia
Francesca Gay
Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. The current treatment landscape for multiple myeloma involves a combination of proteasome inhibitors, immunomodu...
Angela Dispenzieri
Angela Dispenzieri
Monoclonal gammopathy of undetermined significance (MGUS) is the term used for a minimal clonal expansion of plasma cells that is most typically detected by the presence of a small serum monoclonal protein. For most-but not all-patients, th...
Newly Diagnosed Classical Hodgkin Lymphoma: Optimizing Outcomes in a New Therapeutic Era [0.03%]
新诊断的经典型霍奇金淋巴瘤：在新的治疗时代中优化疗效
Andrew M Evens
Andrew M Evens
The treatment landscape for newly diagnosed classical Hodgkin lymphoma (cHL) has seen remarkable advancements over the past decade, which have been fueled by improved prognostication and response-adapted techniques, and primarily driven by ...
Wilma Barcellini,Bruno Fattizzo
Wilma Barcellini
Peripheral autoimmune cytopenias may complicate a fraction of lymphoproliferative disorders (LPD), particularly chronic lymphocytic leukemia, non-Hodgkin B-cell lymphomas, angioimmunoblastic T-cell lymphoma and large granular lymphocytic le...
Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects [0.03%]
follicular淋巴瘤：当前治疗格局与未来展望
Emil Kumar,Jessica Okosun
Emil Kumar
Significant strides have been made in the treatment of follicular lymphoma, leading to improvements in long-term patient outcomes. However, the disease's heterogeneity presents challenges in selecting the optimal therapy at each stage of tr...
Advances in the Management of Relapsed/Refractory CLL and Richter Transformation [0.03%]
复发和难治性慢性淋巴细胞白血病（CLL）及里特转化的治疗进展
Nathalie Javidi-Sharifi,Matthew S Davids
Nathalie Javidi-Sharifi
The management of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), particularly when patients have double-refractory CLL with progression after both covalent Bruton's tyrosine kinase inhibitors (BTKi) and venetoclax, as well as...
Sang Eun Yoon,Won Seog Kim
Sang Eun Yoon
Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of diseases, with over 30 subtypes according to the International Consensus Classification of Mature Lymphoid Neoplasms (ICC) and World Health Organization Classification o...
Francisco Caiado,Markus G Manz
Francisco Caiado
The expansion of hematopoietic cell clones, carrying alterations in genes frequently mutated in hematologic malignancies, in the absence of altered hematopoietic cell counts or otherwise defined disease criteria, is termed clonal hematopoie...